A novel chemical delivery system comprising an ocular sustained release formulation of a 3α, 17α, 21-trihydroxy-5β-pregnan-20-one-BIS- 5-flourouracil codrug

Drug Development and Industrial Pharmacy

Volumn 33, Issue 6, 2007, Pages 677-682

  Howard Sparks, Michelle ^a   Al Ghananeem, Abeer M ^a   Crooks, Peter A ^a,b   Pearson, Andrew P ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b University of Kentucky   (United States)

Author keywords

5 Fluorouracil; Angiogenesis; Chemical delivery; Codrug; Sustained release; Trihydroxy steroid

Indexed keywords

3ALPHA,17ALPHA,21 TRIHYDROXY 5BETA PREGNAN 20 ONE BIS 5 FLOUROURACIL; CARBONIC ACID; ESTER; FLUOROURACIL; PHOSPHATE BUFFERED SALINE; TETRAHYDROCORTISONE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COVALENT BOND; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HYDROLYSIS; DRUG PELLET; DRUG SOLUBILITY; HUMAN; NONHUMAN; PH; SERUM; SUSTAINED DRUG RELEASE; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; ANIMALS; BIOLOGICAL AVAILABILITY; CATTLE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; FLUOROURACIL; HUMANS; MOLECULAR STRUCTURE; PREGNANES; PREGNANOLONE; PRODRUGS; VITREOUS BODY;

EID: 34447125715     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040601134108     Document Type: Article

References (13)

1. Blei, F., Wilson, E., Lynette, M., Paolo, & Rifkin, D. B. (1993). Mechanism of action of angiostatic steroids: Suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J. Cell Physiol., 155, 568-578.
2. Bora, P. S., Sohn, J., Cruz, J., Jha, P., Nishihori, H., Wang, Y., Kaliappan, S., Kaplan, H. J., & Bora, N. S. (2005). Role of complement and complement membrane attack complex in laser-induced choroidal neovascularization. J. Immunol., 174, 491-497.
3. Cardillo, J. A, Farah, M. E., Mitre, J., Morales, P. H., Costa, R. A., Melo, L. A. S., Kuppermann, B., Jorge. R., & Ashton, P. (2004). An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy. Br. J. Ophthalmol., 88, 1201-1205.
4. Cynkowska, G., Cynkowski, T., Al-Ghananeem, A. M., Guo, H., Ashton, P., & Crooks, P. A. (2005). Novel antiglaucoma prodrugs and codrugs of ethacrynic acid. Bioorg. Med. Chem. Lett., 15, 3524-3527.
5. Del Nozal, M. J., Bernal, J. L., Pampliega, A., Pastor, J. C., & Lopez, M. I. (1992). Determination of 5-fluorouracil in vitreous gel and liquid by high-performance liquid chromatography. J. Chromatogr., 607, 183-189.
6. Fialho S. L., & Da Silva-Cunha, A. (2004). New vehicle based on a microemulsion for topical ocular administration of dexamethasone. Clin. Expt. Ophthalmol., 32, 626-32.
7. Frishman, W. H., Kowalski, M., Nagnur, S., Warshafsky, S., & Sica, D. (2001). Cardiovascular considerations in using topical, oral, and intravenous drugs for the treatment of glaucoma and ocular hypertension: Focus on β -adrenergic blockade. Heart Dis., 3, 386-397.
8. Howard-Sparks, M., Al-Ghananeem, A. M., Pearson, A. P., & Crooks, P. A. (2005). Evaluation of O3α -, O21-Di-(N1-methyloxycarbonyl-2, 4-dioxo-5-fluoropyrimidinyl)17α -hydroxy-5β -pregnan-20-one as a novel potential antiangiogenic codrug. J. Enzyme Inhib. Med. Chem., 20, 417-428.
9. Jonas, J. B. (2004). Intraocular availability of triamcinolone acetonide after intravitreal injection. Am. J. Ophthalmol., 137, 560-562.
10. Lee, P., Wang, C. C., & Adamis, A. P. (1998). Ocular neovascularization: an epidemiological review. Surv. Ophthalmol., 43, 245-269.
11. Myles, M. E., Neumann, D. M., & Hill, J. M. (2005). Recent progress in ocular drug delivery for posterior segment disease : emphasis on transscleral iontophoresis. Adv. Drug Deliv. Rev., 57, 2063-2079.
12. Peyman, G. A., & Ganiban, G. J. (1995). Delivery systems for intraocular routes. Adv. Drug Deliv. Rev., 16, 107-123.
13. Speicher, M. A., Danis, R. P., Criswell, M., & Pratt L. (2003). Pharmacologic therapy for diabetic retinopathy, Expert Opin. Emerg. Drugs., 8, 239-250.